Axogen, Inc. Common Stock (AXGN) Stock Price
AXGNStock
$34.62+106.81%52W
Market Cap$2.03B
P/E—
PEG Ratio99.04
Div yield—
Beta1.21
AXGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-9.44%
Price vs S&P 500 (4W)-23.30%
PEG Ratio99.04
VGM Score49.26
AXGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.12 | $0.12 | +1.21%(+$0.00) | |
| Q1 2026 | $0.07 | $0.07 | -2.00%(-$0.00) | |
| Q4 2025 | $0.10 | $0.07 | -27.94%(-$0.03) | |
| Q3 2025 | $0.07 | $0.12 | +76.47%(+$0.05) | |
| Q2 2025 | $0.06 | $0.12 | +100.00%(+$0.06) |
AXGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.19
4.19
4.20
4.19
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
| ELMDElectromed, Inc. | C | B | C | 3.1x | 15.6% | 78.5% | 18.8% | $27.42 |
About Axogen, Inc. Common Stock
Axogen commercializes regenerative medicine solutions for peripheral nerve repair, including grafts, connectors, and protective devices sold in the US, Canada, Europe, and select international markets. The company serves orthopedic and trauma surgeons with clinically validated products designed to improve surgical outcomes. Its portfolio includes Avance Nerve Graft, Axoguard connectors and protectors, and diagnostic assessment tools.